KY-9
| Code | Size | Price |
|---|
| TAR-T32430-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
KY-9 is a bioactive chemical.
CAS:
90278-40-3
Formula:
C10H8Br2N2O3
Molecular Weight:
363.993
Purity:
0.98
SMILES:
CNC(=O)C1=NOC2(C1)C=C(Br)C(=O)C(Br)=C2
References
1. Payne RP, Kl?verpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol. 2010 Oct;84(20):10543-57. doi: 10.1128/JVI.00793-10. Epub 2010 Aug 4. PubMed PMID: 20686036; PubMed Central PMCID: PMC2950555.
2. Kuse N, Rahman MA, Murakoshi H, Tran GV, Chikata T, Koyanagi M, Nguyen KV, Gatanaga H, Oka S, Takiguchi M. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. J Virol. 2015 Jul;89(14):7363-72. doi: 10.1128/JVI.00974-15. Epub 2015 May 13. PubMed PMID: 25972553; PubMed Central PMCID: PMC4473554.
3. Adland E, Hill M, Lavandier N, et al. Differential Immunodominance Hierarchy of CD8(+) T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol. 2018 Jan 30;92(4). pii: e01685-17. doi: 10.1128/JVI.01685-17. Print 2018 Feb 15. PubMed PMID: 29167337; PubMed Central PMCID: PMC5790925.
4. Lu WY, Jackson MF, Bai D, Orser BA, MacDonald JF. In CA1 pyramidal neurons of the hippocampus protein kinase C regulates calcium-dependent inactivation of NMDA receptors. J Neurosci. 2000 Jun 15;20(12):4452-61. PubMed PMID: 10844014.